What he knows that we dont 🤔
Lets digging it … $GNPX
Rep. Tim Moore, who was ranked as the top-performing member of Congress for stock trades in 2025 has made multiple purchases of Genprex, Inc. shares over the past few months.
Putting real money into a high-risk, micro-cap biotech like Genprex (especially repeatedly and while down significantly) usually signals strong personal conviction rather than a casual punt. No one averages down on a tiny, volatile name like this without believing big upside is coming.
In small-cap biotech, conviction like this often pays off massively on one good catalyst (FDA meeting, more data, partnership).
News that many of investors missed 👇
- The Positive preclinical data for GPX-002 (diabetes gene therapy) dropped in early January 2026 showed normalized glucose in animal models. Company requested FDA meeting for Q1 2026 to advance toward human trials.
- JANE STREET GROUP, LLC added 205,180 shares to their portfolio in Q3 2025, for an estimated $1,737,874
- "This past year was instrumental for Genprex as we expanded our preclinical research beyond Type 1 diabetes and into Type 2 diabetes, marking the achievement of a significant milestone in our diabetes gene therapy program, including the successful initiation of preclinical research in Type 2 diabetic animal models," said Ryan Confer, President and Chief Executive Officer. "Furthermore, we have successfully executed our strategic plan to transfer production of GPX-002 to an experienced Contract Development and Manufacturing Organization (CDMO) and to submit a request to the FDA for a meeting regarding our Investigational New Drug (IND)-enabling studies, marking a pivotal step toward human clinical trials."
2026 Q1 could be huge for this name imho
Disclosure: I own shares of GNPX - Always do your own research.
